MVI's immunotherapies are changing the trajectory of PSA and delaying disease progression.
MVI is developing safe immunotherapies for patients in all stages of prostate cancer.
MVI's immunotherapies provide the immune stimulus that help PD-1 inhibitors work better and AR axis inhibitors work longer.
Immune-based monotherapy is the exception rather than the norm in oncology. Our combination strategies for metastatic and non-metastatic prostate cancer are designed to enable checkpoint inhibitors and to maximize the clinical value of standard-of-care therapies for patients, preserve quality of life, and drive adoption.
We believe human data is more valuable than imperfect animal models. Our "Test, Learn, Apply" approach maximizes our knowledge of human response to our immune activating agents.
Rather than asking "how do we provide the most potent vaccine?", we ask, "how do we provide the most effective immunotherapy?"
Our approach is different, but builds on very solid foundations, combining our vaccines with standard-of-care therapies and with checkpoint inhibitors, in mechanistically relevant ways, to maximize clinical response.
We use a simple vaccine technology, manufactured at a low COG, with convenient, minimally invasive delivery, and coordinated combination dosing to keep costs low.
MVI invests heavily in biomarker collection and analysis in each of its trials. We analyze markers of immune activation in blood and in tumors, and utilize fully quantitative PET imaging to learn the impact of our therapies on bone metastases.